cladribine has been researched along with Infection in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (47.37) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Aldridge, J; Coyle, PK; Galazka, A; Giovannoni, G; Leist, TP; Lemieux, C; Nolting, A; Vermersch, P; Walker, B | 1 |
| Boeckh, M; Cheng, GS; Chung, EL; Delaney, C; Halpern, AB; Hill, JA; Huebner, EM; Kiem, ES; Kimball, LE; Leisenring, WM; Liu, C; Pergam, SA; Schonhoff, KG; Walter, RB; Walti, CS; Xie, H | 1 |
| Arima, F; Heike, Y; Kami, M; Kanda, Y; Kim, SW; Mineishi, S; Nakai, K; Saito, T; Takaue, Y; Tanosaki, R; Tobinai, K; Wakasugi, H | 1 |
| Błoński, JZ; Chojnowski, K; Kasznicki, M; Robak, T; Szmigielska-Kapłon, A | 1 |
| Blonski, JZ; Calbecka, M; Ceglarek, B; Dmoszynska, A; Dwilewicz-Trojaczek, J; Gora-Tybor, J; Jamroziak, K; Kasznicki, M; Kloczko, J; Konopka, L; Kowal, M; Kuliczkowski, K; Robak, T; Skotnicki, AB; Stella-Holowiecka, B; Sulek, K; Tomaszewska, A; Warzocha, K; Zawilska, K | 1 |
| Ballabeni, P; Cerny, T; Fey, M; Hess, U; Laurencet, F; Luthi, JM; Plancherel, C; Rufener, B; Zulian, GB | 1 |
| Cheson, BD | 1 |
| Larson, RA; Mick, R; O'Brien, SM; Ratain, MJ; Spielberger, RT | 1 |
| Bosly, A; Delannoy, A; Ferrant, A; Filleul, B; Martiat, P; Michaux, JL; Mineur, P; Montfort, L; Straetmans, N; Van Den Neste, E; Vandercam, B | 1 |
| Błasińska-Morawiec, M; Dwilewicz-Trojaczek, J; Grieb, P; Hansz, J; Hellmann, A; Hołowiecki, J; Kazimierczak, M; Komarnicki, M; Konopka, L; Kotlarek-Haus, S; Krawczyk-Kulis, M; Krykowski, E; Kuratowska, Z; Maj, S; Robak, T; Urasiński, L; Usnarska-Zubkiewicz, L; Zaucha, JM; Zdziarska, B | 1 |
| Hellmann, A; Lewandowski, K; Pawlik, H; Siedlewicz, A; Zaucha, JM | 1 |
| Bennett, B; Canfield, VA; Guiney, P; Nichols, C; Vose, J | 1 |
| Juliusson, G; Liliemark, J; Porwit, A | 1 |
| Gordon, LI; Hakimian, D; Huang, CF; Klein, L; Kong, LR; Kuzel, TM; Tallman, MS; Variakojis, D; Wollins, E; Zanzig, C | 1 |
| Bastie, JN; Castaigne, S; Cazals-Hatem, D; D'Agay, MF; Dabout, D; Daniel, MT; Degos, L; Dombret, H; Flandrin, G; Glaisner, S; Noel-Walter, MP; Poisson, D; Rabian, C | 1 |
| Dmoszyńska, A; Kowal, M; Lech-Marańda, E; Robak, T; Wrzesień-Kuś, A | 1 |
| Blasińska-Morawiec, M; Bloński, JZ; Ceglarek, B; Dmoszyńska, A; Dwilewicz-Trojaczek, J; Grieb, P; Hellmann, A; Kasznicki, M; Konopka, L; Kotlarek-Haus, S; Krykowski, E; Maj, S; Mrugala-Spiewak, H; Nowak, W; Potoczek, S; Robak, T; Skotnicki, AB; Urasiński, I; Zdziarska, B | 1 |
| Boguradzki, P; Błoński, JZ; Calbecka, M; Ceglarek, B; Dmoszyńska, A; Dwilewicz-Trojaczek, J; Góra-Tybor, I; Kasznicki, M; Konopka, L; Kuliczkowski, K; Moskwa-Sroka, B; Nowak, W; Robak, T; Skotnicki, AB; Stella-Hołowiecka, B; Sułek, J; Wołowiec, D | 1 |
| Kontoyiannis, DP; Samonis, G | 1 |
2 review(s) available for cladribine and Infection
| Article | Year |
|---|---|
Infectious and immunosuppressive complications of purine analog therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cladribine; Humans; Immune Tolerance; Infections; Pentostatin; Purines; Vidarabine | 1995 |
Infectious complications of purine analog therapy.
Topics: Antimetabolites, Antineoplastic; Cladribine; Humans; Immune Tolerance; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Vidarabine Phosphate | 2001 |
11 trial(s) available for cladribine and Infection
| Article | Year |
|---|---|
Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial comparison with conventional myeloablative transplantation.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cladribine; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immune System; Immunosuppression Therapy; Infections; Kinetics; Lymphocyte Count; Lymphocyte Subsets; Male; Middle Aged; Regeneration; Transplantation Conditioning; Transplantation, Homologous | 2003 |
Activity of cladribine combined with etoposide in heavily pretreated patients with indolent lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Etoposide; Female; Humans; Infections; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Recurrence; Survival Analysis; Treatment Outcome | 2005 |
Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG C
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Female; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Neutropenia; Remission Induction | 2006 |
The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Hematologic Diseases; Humans; Immunocompromised Host; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms, Second Primary; Prednisone; Prospective Studies; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome | 2007 |
Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Chi-Square Distribution; Cladribine; Diarrhea; Digestive System Diseases; Drug Administration Schedule; Fatigue; Female; Fever; Hematologic Diseases; Humans; Immunocompromised Host; Infections; Infusions, Intravenous; Logistic Models; Lymphoproliferative Disorders; Male; Middle Aged; Treatment Outcome | 1996 |
2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cladribine; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Immunologic Factors; Infections; Infusions, Intravenous; Interferon-alpha; Leukemia, Hairy Cell; Male; Middle Aged; Remission Induction; Splenectomy; Treatment Outcome | 1996 |
2-Chlorodeoxyadenosine as initial therapy for advanced low grade lymphomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Cladribine; Disease-Free Survival; Female; Humans; Infections; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Treatment Outcome | 1997 |
Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin's lymphoma.
Topics: Cladribine; Disease Progression; Dose-Response Relationship, Drug; Humans; Infections; Leukopenia; Lymphoma, Non-Hodgkin; Survival Rate; Thrombocytopenia | 1997 |
Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Infections; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms, Second Primary; Prognosis; Survival Analysis; Treatment Outcome | 1998 |
Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cladribine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Incidence; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Male; Middle Aged; Neutropenia; Poland; Prednisone; Prospective Studies; Remission Induction; Survival Rate; Thrombocytopenia; Treatment Outcome | 2000 |
Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cladribine; Cohort Studies; Cyclophosphamide; Female; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Pancytopenia; Treatment Outcome; Vomiting | 2001 |
6 other study(ies) available for cladribine and Infection
| Article | Year |
|---|---|
Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets.
Topics: Adolescent; Adult; Age Factors; Aged; Cladribine; Humans; Infections; Lymphocyte Count; Lymphopenia; Middle Aged; Multiple Sclerosis; Tablets; Young Adult | 2021 |
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cladribine; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Infections; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Mitoxantrone; Respiratory Tract Infections; Sepsis | 2023 |
Infectious complications after 2-chlorodeoxyadenosine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cladribine; Cohort Studies; Disease Susceptibility; Female; Fever; Hematologic Diseases; Herpesviridae Infections; Humans; Immunologic Deficiency Syndromes; Incidence; Infections; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Retrospective Studies; Risk Factors; Waldenstrom Macroglobulinemia | 1996 |
2-Chlorodeoxyadenosine treatment in the Sezary syndrome.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cladribine; Female; Humans; Infections; Male; Middle Aged; Neutropenia; Sezary Syndrome; Thrombocytopenia; Treatment Failure | 1997 |
Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Marrow; CD4 Lymphocyte Count; Cladribine; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infections; Interferon-alpha; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Second Primary; Opportunistic Infections; Pentostatin; Remission Induction; Splenectomy; Survival Rate | 1999 |
Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Disease-Free Survival; Drug Evaluation; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Neutropenia; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 2000 |